| Fiume L, Baglioni M, Busi C, et al.
The enhancement of interstitial transport of a doxorubicin-lactosaminated albumin conjugate by imatinib: in rat hepatocellular carcinoma it is not preferentially higher than that in liver and bone marrow. [Journal Article, Research Support, Non-U.S. Gov't]
Eur J Pharm Biopharm 2009 Aug; 72(3):630-1.
Abstract | Full Citation | Find Related Articles | | Yagasaki F, Niwa T, Abe A, et al.
Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. [Journal Article]
Rinsho Ketsueki 2009 Jun; 50(6):481-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Stacchiotti S, Marrari A, Tamborini E, et al.
Response to imatinib plus sirolimus in advanced chordoma. [JOURNAL ARTICLE]
Ann Oncol 2009 Jul 1.
Abstract | Full Citation | Find Related Articles | | Keller G, Brassat U, Braig M, et al.
Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. [JOURNAL ARTICLE]
Hematol Oncol 2009 Jul 1.
Abstract | Full Citation | Find Related Articles | | Terabe F, Kitano M, Kawai M, et al.
Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. [JOURNAL ARTICLE]
Mod Rheumatol 2009 Jul 1.
Abstract | Full Citation | | Choi WH, Kim S, Hyung WJ, et al.
Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. [Journal Article]
Yonsei Med J 2009 Jun 30; 50(3):437-40.
Abstract | Full Citation | | Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, et al.
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. [Journal Article, Research Support, Non-U.S. Gov't]
PLoS One 2009; 4(7):e6124.
Abstract | Full Citation | | Jabbour E, Jones D, Kantarjian HM, et al.
Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. [JOURNAL ARTICLE]
Blood 2009 Jun 30.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Grosso S, Puissant A, Dufies M, et al.
Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. [JOURNAL ARTICLE]
Mol Cancer Ther 2009 Jun 30.
Abstract | Full Citation | Find Related Articles | | Li YF, Deng ZK, Xuan HB, et al.
Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy. [Journal Article]
Chin Med J (Engl) 2009 Jun 20; 122(12):1413-7.
Abstract | Full Citation |   |
|
| |
Advertise on this site.
|
